Future of weight loss

More than 40% of Americans are now classified as obese while 75% of adults are either overweight or obese. A new group of drugs called GLP-1 receptor agonists have come on the scene to help in the battle to lose weight. Are they as good as we think?

You may have heard about them or some of their brand names like Zepbound, Wegovy, and Ozempic. The use of these drugs has exploded in popularity to the point where companies like Lilly and Novo Nordisk have had problems keeping up with demand. There is nothing magical about the science behind these drugs. GLP-1 mimics a protein naturally produced by our small intestines. The receptors for these medicines are located across the body. They help us lose weight because receptors in the gastrointestinal tract slow down and send signals to the brain that give us a sense of feeling full.

There are some side effects but nothing too serious for most patients. We are still learning how these medications impact the body. They are currently approved for treating diabetes, obesity, and those with a history of cardiovascular disease in people who are overweight. There are a few drawbacks to these drugs at present.

Typically, GLP-1 agonists are administered as injections in the abdomen, upper arms, outer thighs, or upper buttocks via a syringe and needle or a pre-filled dosing pen. The shots are generally taken once a day or once a week.

For many, this is a big turn-off. Fortunately, you will be able to take tablets soon. The typical weight loss is from 5-15% of body weight over at least 12 months. But GLP-1 is no quick fix. Like exercise, you must stick with it. If you stop taking it, most people regain the weight they lost. And you can’t expect to magically lose weight while you continue to eat all that junk food you get.

The second drawback is the expense. These medications’ list price is around $1,000 a month to $1,400 a month. Without insurance, we are talking $12,000 plus per year for these drugs. Many insurance plans cover some portion of GLP-1 costs, but the extent of coverage can vary significantly. You probably are wondering whether Medicare covers GLP-1 medications. They do for certain medically accepted indications such as heart attack or cardiovascular disease but not for weight management. To qualify, you must have a BMI of 30 or higher, or 27 or higher with comorbidities like high blood pressure, high cholesterol, or type 2 diabetes. They are currently covered through Part D plans.

An entirely new team of individuals, including a retired congressman, a surgeon, and a talk-show host could play pivotal roles in how the government goes about safeguarding America’s health.

Coinsurance amounts are pegged to the list price of drugs. As such, Medicare beneficiaries who qualify could still face monthly costs of $250 to $430 before they reach the annual out-of-pocket drug spending established by the Inflation Reduction Act (IRA). The IRA cap for out-of-pocket expenses were around $3,300 in 2024 and will be $2,000 in 2025. Most retirees living on modest incomes would still find the cost of GLP-1 prohibitive.

In November 2024, the Biden Administration proposed that Medicare and Medicaid cover obesity medications. In doing so, they sidestepped a twenty-year-old piece of legislation that prevented Medicare from covering drugs for ‘weight loss.’ The new proposal specifies that the drugs would be covered to treat the disease of obesity and prevent related conditions. Those conditions are serious and include diabetes, high blood pressure, cardiovascular disease, sleep apnea, fatty liver disease, and arthritis.

The classification would also mean that every state Medicaid program would be required to cover the drugs starting in 2026. Between the two programs, an additional 7.4 million Americans would gain coverage. The price tag would be high, at least $36 billion over a decade. However, there are more obesity drugs in the pipeline and prices should fall as competition heats up. Starting in 2025, Medicare will also be able to negotiate a lower price for Wegovy as well as many other popular drugs.

As for the future, the costs and usage of GLP-1 medications could change significantly under the second Trump Administration. An entirely new team of individuals, including a retired congressman, a surgeon, and a talk-show host could play pivotal roles in how the government goes about safeguarding America’s health.

Under Robert F. Kennedy, an environmental lawyer, politician, and anti-vaccine organizer, we can expect radically different views and actions in health care, medicine, food safety, and science research. Early indications are that Kennedy, who would run the Department of Health and Human Services, is not a big fan of Ozempic. He does not believe that using popular GLP-1 drugs is ever going to make America healthy again. His remedy would be to provide good food to Americans. He believes that providing three nutritious meals a day to all Americans would solve obesity and diabetes overnight. The problem is that for many Americans the admonition to change your diet, eat less, and exercise more has failed to dent the problem. Why not give the country an avenue that shows a much better chance of success over the long term?



Bill Schmick is a founding partner of Onota Partners, Inc., in the Berkshires.

The views expressed here are not necessarily those of The Lakeville Journal and The Journal does not support or oppose candidates for public office.

Latest News

Roomful of Blues set for April 17 show at Infinity Hall in Norfolk
Photo provided

NORFOLK –Roomful of Blues, the Rhode Island-based band hailed by DownBeat magazine as being “in a class by themselves,” will bring its mix of blues, jump, swing, boogie-woogie and soul to Infinity Hall in Norfolk on Friday, April 17, at 8 p.m.

The long-running group, formed in 1967, is touring behind its Alligator Records album Steppin’ Out!, released in late 2025.

Keep ReadingShow less

Robert E. Stapf Sr.

Robert E. Stapf Sr.

MILLERTON — Robert E. Stapf Sr. (Bobbo), a devoted husband, loving father, grandfather, great grandfather, brother and friend to many, passed away peacefully on April 9, 2026, at the age of 77, happily at home surrounded by lots and lots of love and with the best care ever.

Bob was born Jan. 16, 1949, to the late Peter and Dorothy (Fountain) Stapf. He began working at an early age, met his forever love, Sandy, in 7th grade and later graduated from Pine Plains Central School.

Keep ReadingShow less

Michael Joseph Carabine

Michael Joseph Carabine

SHARON — Michael Joseph Carabine, 81, of Sharon, Connecticut, passed away on the morning of Friday, April 3, 2026, at Bryn Mawr Hospital in Bryn Mawr, Pennsylvania. He was the beloved husband of the late Angela Derrico Carabine and loving father to Caitlin Carabine McLean.

Michael was born on April 23, 1944, in Bronx, New York. He was the son of the late Thomas and Kathleen Carabine of New York.

Keep ReadingShow less
google preferred source

Want more of our stories on Google? Click here to make us a Preferred Source.

Chion Wolf brings ‘Audacious’ radio show to Winsted with show-and-tell event
Nils Johnson, co-founder and president of The Little Red Barn Brewers in Winsted, hosted Chion Wolf and her Connecticut Public show “Audacious LIVE: Show and Tell,” which was broadcast on April 8, drawing a sold-out crowd.
Jennifer Almquist

The parking lot of The Little Red Barn Brewers in Winsted was full on Wednesday, April 8, as more than 100 people from 43 Connecticut towns — including New Haven and Vernon — arrived carrying personal treasures for a live taping of “Audacious LIVE Show & Tell.”

Chion Wolf, host and producer of Connecticut Public’s “Audacious,” and her crew, led by production manager Maegn Boone, brought the program to the packed brewery for an evening of story-driven conversation and shared keepsakes.

Keep ReadingShow less
Marge Parkhurst, the preservation detective

Marge Parkhurst with a collection of historic nails recovered from wall cavities during restoration work.

Photo courtesy of Marge Parkhurst/Cottage & Country Painting Company
Walls still surprise me. If you look hard enough, you can find buried treasure.
Marge Parkhurst

After nearly 50 years of painting some of Litchfield County’s oldest homes and landmark properties, Marge Parkhurst has developed an eye for the past—reading the clues left behind in stenciled vines, forgotten bottles and newspapers tucked into walls, each revealing a small but vivid piece of Connecticut history.

Parkhurst was stripping wallpaper in a farmhouse in Colebrook — the kind of historic home she has spent decades restoring — when she noticed something odd. Three layers of paper had already come off — each one a different era’s idea of decoration — and beneath them, just barely visible under dull, off-white plaster, a pattern emerged.

Keep ReadingShow less
Wings of Spring performance at the Mahaiwe Theater
Adam Golka
Provided

On Sunday, April 19, at 4 p.m., Close Encounters With Music (CEWM) presents On the Wings of Song at the Mahaiwe Performing Arts Center in Great Barrington.

The program focuses on Robert Schumann’s spellbinding song cycle Dichterliebe (“A Poet’s Love”), a setting of sixteen poems by Heinrich Heine that explores love, longing, and the redemptive power of beauty. Featured artists include John Moore, baritone; Adam Golka, pianist; Miranda Cuckson, viola; and Yehuda Hanani, cello.

Keep ReadingShow less
google preferred source

Want more of our stories on Google? Click here to make us a Preferred Source.

google preferred source

Want more of our stories on Google? Click here to make us a Preferred Source.